| RTX |
Report |
Adj. EPS (Q2 2026) |
BEAT |
pred ~$1.82 vs cons $1.67 |
HIGH |
| RTX |
Report |
Net Sales (Q2 2026) |
BEAT |
pred ~$23.2B vs cons $22.9B |
MEDIUM |
| RTX |
Report |
Backlog (Q2 2026) |
IN-LINE |
pred ~$280-282B vs cons $279.5B |
MEDIUM |
| RTX |
Guide |
Adj. EPS FY2026 (FY2026) |
UNCHANGED |
guide ~$6.85-$7.05 (mid $6.95) vs cons $6.95 |
MEDIUM |
| RTX |
Guide |
Adj. Sales FY2026 (FY2026) |
UNCHANGED |
guide ~$93.5-$94.5B (mid $94.0B) vs cons $94.3B |
MEDIUM |
| RTX |
Guide |
FCF FY2026 (FY2026) |
UNCHANGED |
maintain $8.25-$8.75B vs cons $8.60B |
HIGH |
| RTX |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
MEDIUM |
| RTX |
Return |
5-day cumulative residual |
-3.0% (FADE) |
FADE — H2 implied math constructive limits severity vs 2026Q1; B archetype does not recover fully in 5 days |
MEDIUM |